AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06757881 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :5.0×10^8（Third dose group）
Description: Different dose groups
Study NCT06758414 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Chronic Pain (CBT-CP)
Description: Cognitive Behavioral Therapy for Chronic Pain (CBT-CP) will be conducted in accordance with the Cognitive Behavioral Therapy for Chronic Pain: Therapist Manual and the VA Evidence-Based Practice (EBP) roll-out training. CBT-CP consists of a 12-session protocol, including an initial assessment session (BL assessment; Session 1), 10 content-specific sessions (pain education, goal-setting, cognitive and behavioral skill building; Sessions 2-11), and a booster session scheduled approximately one month after the final CBT-CP session (Session 12). Participants randomized to the CBT-CP condition (n = 30) will complete one 60-minute individual session per week. Each CBT-CP session will be led by a trained study interventionist using a manualized curriculum, following a basic structure including review of previous session material, introduction of new information or skills, and discussion of how to implement learned material into a home action plan.
Study NCT06758414 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health & Wellness (H&W)
Description: Health \& Wellness (H\&W) was developed by VISN 5 MIRECC investigators and consists of psychoeducation on topics related to physical and emotional wellbeing. Its structure is similar to CBT-CP (10 weekly individual 60-minute sessions, no booster session). Each Health \& Wellness session will be led by a trained interventionist using a manualized curriculum that includes review of previous session material, introduction of new information, and discussion of a range of health-related topics (physical activity/exercise, nutrition/healthy eating, managing medications and side effects, and addictive behaviors (e.g., substance use, gambling, eating) that do not include pain. Typical sessions include discussion of the impact of the topic on overall health and well-being, identifying benefits and challenges to improving or maintaining health in that area, and strategies to address challenges in that area.
Study NCT06284785 — intervention group
Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Patients included in our obese patient group are all scheduled to undergo bariatric surgery
Study NCT06757738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRX-100
Description: CEN inhibitor, dosage form - capsules, dosing regimen - QD
Study NCT06757738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, dosage form - capsules, dosing regimen - QD
Study NCT06758245 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: femoral and anterior sciatic nerve block
Description: First, in the supine position, the USG probe is placed below the inguinal crease. The femoral nerve is located lateral to the femoral artery, above the iliopsoas muscle. Once the needle tip reaches the nerve, simultaneous nerve stimulation is applied. Patellar movement is observed due to quadriceps muscle contraction upon needle placement. After a negative aspiration test, 20 ml of local anesthetic is injected.For the anterior sciatic block, while the patient was in the supine position, a convex ultrasound (USG) probe was placed transversely approximately 10 cm distal to the inguinal ligament. After visualizing the sciatic nerve as a hyperechoic flat structure, the nerve stimulator was set to 1-1.5 mA, 0.1 ms, and 1 Hz. Using an in-plane technique, the block needle was advanced. Upon reaching the sciatic nerve, when contractions in the calf, foot, or big toe continued at a current of 0.3-0.5 mA, 20 ml of 0.5% bupivacaine was administered following a negative aspiration test.
Study NCT06758245 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: femoral and popliteal sciatic nerve block
Description: The ultrasound probe is placed transversely at the popliteal crease. The first structure seen is the popliteal artery. Just above and lateral to the artery, the tibial nerve appears as a hyperechoic, oval, and round structure. After identifying the tibial and peroneal nerves, the probe is moved proximally, and it is observed that the nerves join about 5-10 cm above the popliteal crease. The needle is advanced using an in-plane technique. After obtaining the first sciatic nerve stimulation, 20 cc of 0.5% bupivacaine is injected following a negative aspiration test.
Study NCT06757686 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mousetrap appliance
Description: two mini-implant will be inserted in the palate. then, the mousetrap appliance will be inserted on the mini-implant and activated with power chain.
Study NCT06757972 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Tele Rehab
Description: Tele rehabilitation intervention is 6 months standardized program aimed to provide special rehabilitation services to patients with mobility impairments in rural areas without the need for them to travel to healthcare facility in big cities. The program consists of standard exercises addressing key components of mobility impairments.
Study NCT06757972 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Formal Rehab
Description: After formal rehabilitation is completed, some impaired mobility victims re-access services; no attempt will be made to stop the control group from accessing further care, in either a public or private setting. However, physical activity participation will be assured during monthly phone call by a blinded -research assistant. Participants in this group will undergo three assessments at baseline, 6 and 12 months
Study NCT06757296 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic SASI
Description: Endoscopic conversion to sleeve gastrectomy to SASI
Study NCT06756334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]AlF-PSMA-N5
Description: Each subject receive a single intravenous injection of \[18F\]AlF-PSMA-N5, and undergo PET/CT imaging within the specificed time.
Study NCT05471050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAC
Description: Tacrolimus is given at a dose of 0.03mg/kg·d, and the dose is adjusted to maintain the trough concentration of tacrolimus at approximately 3-5 ng/mL for 12 weeks.
Study NCT05471050 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Danazol
Description: Danazol is given at 200mg bid for 12 weeks.
Study NCT05471050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danazol
Description: Danazol is given at 200mg bid for 12 weeks.
Study NCT04992494 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBCT-Telephone
Description: Mindfulness-based cognitive therapy (MBCT) comprised of 8 weekly classes delivered via telephone by a licensed clinical psychologist certified to teach MBCT, following treatment fidelity guidelines from NIH's Behavioral Change Consortium.~The program involves a commitment of 1 hour per week for 8 weeks. During the sessions, subjects will learn cognitive and mindfulness skills to help manage and cope with depression. Each weekly session consists of: check-in, instruction, skill building, discussion, and a home-based practice assignment.
Study NCT04992494 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBCT-Video
Description: Mindfulness-based cognitive therapy (MBCT) comprised of 8 weekly classes delivered via WebEx video-conferencing by a licensed clinical psychologist certified to teach MBCT, following treatment fidelity guidelines from NIH's Behavioral Change Consortium.~The program involves a commitment of 1 hour per week for 8 weeks. During the sessions, subjects will learn cognitive and mindfulness skills to help manage and cope with depression. Each weekly session consists of: check-in, instruction, skill building, discussion, and a home-based practice assignment.
Study NCT06756334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]F-DCFPyL
Description: Each subject receive a single intravenous injection of \[18F\]F-DCFPyL, and undergo PET/CT imaging within the specificed time.
Study NCT05773599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laughter yoga
Description: A pre-test will be applied to evaluate sleep quality and life satisfaction. Laughter yoga will be applied one day apart to the experimental group with a low sleep quality score. After dasa, sleep quality and life satisfaction will be evaluated again with
Study NCT06756789 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Laparoscopic Roux-en Y Gastric bypass (RYGB)- Conventional approach
Description: The procedure involves creating a small gastric pouch from the upper portion of the stomach, which is then directly connected to the small bowel, in a roux- enY fashion with another jejune-jejunal anastamosis bypassing a large part of the stomach and the duodenum. This results in reduced food intake and decreased nutrient absorption. In this arm, standard limb lengths of 75cms BP limb and 125cms Alimentary limb were measured and performed, irrespective of the total bowel length
Study NCT05316649 — intervention group
Intervention type: OTHER
Intervention: Measurement of external blood loss
Description: Measurement of external blood loss
Study NCT05316649 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serum Hemoglobin concentration
Description: Serum Hemoglobin concentration
Study NCT04737889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Induction Chemotherapy: 375mg/m2, Intravenous administration on day 0 of each 3-week cycle until disease progression/stable disease or unacceptable toxicity develops, up to 6 cycles.
Study NCT04737889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Induction Chemotherapy: 25mg, oral administration on day 1 to 10 of each 3-week cycle until disease progression/stable disease or unacceptable toxicity develops, up to 6 cycles.~Maintenance Treatment: 10mg oral administration on day 1 to 21 repeated every 4 weeks until disease progression or unacceptable toxicity develops, up to 12 cycles.
Study NCT04737889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Induction Chemotherapy: 3mg/m2, Intravenous administration (pumping for 3h) on day 1 of each 3-week cycle until disease progression/stable disease or unacceptable toxicity develops, up to 6 cycles.
Study NCT04737889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Induction Chemotherapy: 150mg/m2/d oral administration on day 1 to 10 of each 3-week cycle until disease progression/stable disease or unacceptable toxicity develops, up to 6 cycles.
Study NCT04718116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group tapentadol 50 mg
Description: patients in group A will receive tapentadol 50 mg p.o 3 times daily for two days
Study NCT04718116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: group tapentadol 75 mg
Description: patients in group B will receive tapentadol 75 mg p.o 3 times daily for two days
Study NCT04718116 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: group tramadol 100 mg
Description: patients in group C will receive tramadol 100 mg p.o 3 times daily for two days
Study NCT06756789 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Roux-en Y Gastric bypass (RYGB)- Tailored approach
Description: The procedure involves creating a small gastric pouch from the upper portion of the stomach, which is then directly connected to the small bowel, in a roux- enY fashion with another jejune-jejunal anastamosis bypassing a large part of the stomach and the duodenum. This results in reduced food intake and decreased nutrient absorption. In this arm, limb lengths are tailored according to the total small bowel length, 1/3rd of the total bowel length is measured and in that 3/8th and 5/8th were kept as BP limb and alimentary limb respectively.
Study NCT06758349 — intervention group
Intervention type: OTHER
Intervention: General questionnaire
Description: Demographic, medical history, and musical activity data will be collected using a specifically designed questionnaire
Study NCT06758349 — intervention group
Intervention type: OTHER
Intervention: Pain Questionnaire
Description: Questionnaire that evaluate pain and functional limitation during last week, last six months e during the carrier.~The impact of painful symptoms on professional and non-professional activities , during the last week, will be assessed using the QuickDASH scale for the upper limb, the Modified Oswestry Low Back Disability Index for low back pain, and the Neck Disability Index questionnaire for cervico-dorsalgia
Study NCT06758349 — intervention group
Intervention type: OTHER
Intervention: Postural assessment without musical instrument in sitting position
Description: Postural assessment without the instrument in a sitting position. Disposable ECG electrodes will be applied to the following anatomical landmarks: Spinous process C7 (C7), Right shoulder acromion (RS), Left shoulder acromion (LS), Right scapula inferior angle (RIA), Left scapula inferior angle (LIA), Spinous process L3 (L3), Intergluteal line (IG), vertex. The Physical Analyzer Portable will be used: a non-invasive, portable device that allows calibrated photo acquisition on the frontal and sagittal planes and subsequent data processing through dedicated software. On frontal plane they will be calculated: Trunk inclination, Head-neck inclination, Right and left shoulder height, Right and left shoulder width, right and left scapula-rachis distance. On sagittal plane they will be calculated: cervical and lumbar arrow, right and left shoulder distance.
Study NCT06758349 — intervention group
Intervention type: OTHER
Intervention: Postural assessment with the instrument in sitting position.
Description: Postural assessment with the instrument in a sitting position. Disposable ECG electrodes will be applied to the following anatomical landmarks: Spinous process C7 (C7), Right shoulder acromion (RS), Left shoulder acromion (LS), Right scapula inferior angle (RIA), Left scapula inferior angle (LIA), Spinous process L3 (L3), Intergluteal line (IG), vertex. The Physical Analyzer Portable will be used: a non-invasive, portable device that allows calibrated photo acquisition on the frontal and sagittal planes and subsequent data processing through dedicated software. On frontal plane they will be calculated: Trunk inclination, Head-neck inclination, Right and left shoulder height, Right and left shoulder width, right and left scapula-rachis distance. On sagittal plane they will be calculated: cervical and lumbar arrow, right and left shoulder distance.
Study NCT05107453 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: The Investigational Medical Product (IMP) is levobupivacaine 0,25%, 2,5 mg/ml, solution for injection. The dosage scheme is as following:1.25 mg/kg levobupivacaine 0,25%, with a maximum of 100 mg, As the standard anaesthetic management already contains levobupivacaine, a maximum dosage of 100 mg (40 ml) levobupivacaine will be administered during the SAPB.~The IMP is given via ultrasound-guided infiltration, in plane, midaxillary, 4-5th rib, between the latissimus dorsi and serratus anterior muscle, at the end of surgery.
Study NCT05051709 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corrective osteotomy
Description: First metatarsal distal corrective osteotomy
Study NCT05051709 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fusion of First ray
Description: Fusion of first ray with soft tissue procedure
Study NCT06756516 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Feldenkrais Method and Core stabilization
Description: Balance exercises from supine lying position using Feldenkrais style, plus core stabilization exercises.
Study NCT06366087 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atropine Sulfate Ophthalmic Solution USP, 1%
Description: Atropine Sulfate Ophthalmic Solution, USP 1% manufactured by Bausch \& Lomb Americas Inc., is a sterile topical anti-muscarinic indicated for mydriasis, cycloplegia, and penalization of the healthy eye to treat amblyopia. Each mL of Atropine Sulfate Ophthalmic Solution USP, 1% contains the active ingredient atropine sulfate 10 mg, equivalent to 8.3 mg of atropine. Inactive ingredients are boric acid, hydroxypropyl methylcellulose, and water for injection, USP; hydrochloric acid and/or sodium hydroxide may be added to adjust pH (3.5 to 6.0). Atropine Sulfate Ophthalmic Solution, USP 1% will be supplied in 0.4 mL single-dose vials and will be administered as a single dose to a single participant. 100 μL of Atropine Sulfate Ophthalmic Solution, USP 1% will be given sublingually by pipette to deliver 1.0 mg of atropine sulfate. Before administration, participants will be told to swallow. Once given, participants will be told to try not to swallow for 30 seconds and then swallow normally.
Study NCT06366087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atropine Sulfate Injection, USP 8 mg/20 mL (0.4 mg/mL)
Description: Atropine sulfate injection, USP is a muscarinic antagonist used for temporary blockade of severe/life-threatening muscarinic effects and to treat symptomatic bradycardia. Atropine Sulfate Injection, USP, 8 mg/20 mL (0.4 mg/mL) manufactured by Fresenius Kabi is a sterile, nonpyrogenic, isotonic, clear solution of atropine sulfate in water for injection with sodium chloride sufficient to render the solution isotonic. Each mL contains atropine sulfate, 0.4 mg; benzyl alcohol, 9 mg; and sodium chloride 9 mg; it may also contain sulfuric acid for pH adjustment, pH 3.5 (3.0 to 3.8). Atropine Sulfate Injection, USP will be supplied in 8 mg/20 mL multidose vials (0.4 mg/mL). Each vial will be used to administer multiple doses to multiple participants. 2.5 mL will be injected into the mid-anterolateral thigh to deliver 1.0 mg of atropine sulfate. Vials will be dated/timed and will not be given after 24 hours of first entry.
Study NCT05055817 — intervention group
Intervention type: OTHER
Intervention: bloody stool group
Description: bloody stool appear in the hospitalized neonate
Study NCT06360367 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HI-FLY Curriculum
Description: Participants receive the standard HI-FLY Curriculum over 6 weeks.
Study NCT06360367 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HI-FLY Curriculum + PortionSize Ed app
Description: Participants receive the standard HI-FLY Curriculum over 6 weeks and the PortionSize Ed mobile app.
Study NCT05828654 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Focus Group Discussions and Semi-structured Interviews
Description: Community representatives will be asked to participate in either 1:1 semi-structured interviews with a research staff member or to engage in focus group discussions with other community members. These interviews and discussions will gather broad perspectives on resource and training needs for community lay navigators and inform the adaptation of existing Peer Connect training materials
Study NCT05828654 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Training community lay navigators
Description: Lay navigators identified from among the recruited community representatives will be trained either in-person or virtually by research staff members in motivational interviewing and other strategies to provide psychosocial support to older socially disadvantaged adults with cancer. For community lay navigators and inform the adaptation of existing Peer Connect training materials.
Study NCT05280509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TL-895
Description: TL-895 is an experimental tyrosine kinase inhibitor anticancer drug taken by mouth.
Study NCT05280509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib is an FDA-approved janus kinase inhibitor anticancer drug taken by mouth.
Study NCT06756516 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Core stability exercises
Description: trunk deep muscles activation and engaging using exercises as bridging, side bridging, plank, side plank and McGill Abdominal
Study NCT06757101 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vojta Therapy
Description: Exercises will be performed in supine, lateral, decubitus and reflex crawling. Exercises will include Stretching's, ROMs Exercises, Stimulation of 10 different zones for locomotion \& gentle pressure applied to stimulation areas. Frequency of exercises will be 2 times a week, duration 40 minutes per day.
Study NCT06757101 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bobath Therapy
Description: Exercises will be performed in supine, lateral, prone and standing position. Exercises includes stretching Exercises, ROMs, Quadruped imbalance exercise, Imbalance from the kneeling exercise, Cervant Knight exercise, Tandem walk, Kicking a ball, Step climbing, marching at one place with alternate foot Frequency of exercises will be 2 times a week, duration 40 minutes per day.
Study NCT06757101 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combined Vojta and Bobath Therapy
Description: Combined Vojta and Bobath exercises along with the conventional treatment. Frequency of exercises will be 2 times a week, duration 40 minutes per day.
Study NCT06757712 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non linear periodization exercise
Description: The non-linear periodized resistance training program follows a 12-week schedule with varying intensity levels across three training days per week. The intensity fluctuates between very light (VL), light (L), moderate (M), heavy (H), and very heavy (VH) workouts, distributed strategically throughout the week. Each training day implements different intensity levels, and an active rest day follows any workout session.